Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Would you treat a patient with an N2 ipsilateral recurrence following re-resection of bronchial stump recurrence?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
In resected N2 NSCLC, what nodal pathologic characteristics prompt you to recommend PORT?
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
What is the recommendation for persistent PET uptake and elevated catecholamines at 4 months following subtotal resection and adjuvant radiation for a thoracic secretory paraganglioma?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
Is there a role for focal radiation in peritoneal mesothelioma following cytoreductive surgery/ HIPEC?
What are your top takeaways in thoracic cancers from ESMO 2025?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?